N-Acetyl Cysteine Supplementation in Therapy Refractory Major Depressive Disorders
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the efficacy of N-acetylcysteine (NAC) add-on to
antidepressant medication in treating patients who do not relieve during standard
antidepressant treatment for 6 weeks at least. Meanwhile, secondary outcomes will include
changes in some biomarkers and on specifically local brain activity (functional Magnetic
Resonance Imaging, fMRI) and white matter integrity (Diffusion Tensor Imaging, DTI). The
hypothesis of this study is that NAC has positive effects on refractory major depressive
disorder patients with increased inflammatory activity.
Phase:
N/A
Details
Lead Sponsor:
Tianjin Anding Hospital
Treatments:
Acetylcysteine N-monoacetylcystine Serotonin and Noradrenaline Reuptake Inhibitors Serotonin Uptake Inhibitors